Welcome to our dedicated page for Enhabit SEC filings (Ticker: EHAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Enhabit, Inc. (NYSE: EHAB) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a public issuer. Enhabit, which operates as Enhabit Home Health & Hospice, files reports with the U.S. Securities and Exchange Commission that describe its home health and hospice business, financial performance, governance matters, and executive compensation arrangements.
Through its Form 8-K filings, Enhabit reports material events such as quarterly earnings releases, participation in investor conferences, leadership changes, and stockholder meeting results. For example, the company has filed 8-Ks to furnish its earnings press releases and supplemental information for quarters ended March 31, June 30, and September 30, as well as to describe a CEO transition plan, retention awards for senior officers, and approval of the Enhabit, Inc. 2025 Equity and Incentive Compensation Plan at its annual meeting.
Enhabit’s filings also identify its common stock as registered under Section 12(b) of the Exchange Act and traded on the New York Stock Exchange under the symbol EHAB. The company uses its SEC reports to explain its use of non-GAAP measures such as Adjusted EBITDA, Segment Adjusted EBITDA, Adjusted EPS, and Adjusted free cash flow, and to discuss how unusual or nonrecurring items affect the reconciliation to GAAP results. Same-store comparison methodology for home health and hospice locations is also described in these materials.
On this page, users can review Enhabit’s SEC filings in chronological order, including 8-Ks that detail results of operations and financial condition, regulation FD disclosures, equity plan approvals, and stockholder voting outcomes. Stock Titan’s tools surface these documents alongside AI-powered summaries that highlight key points, helping readers quickly understand how each filing relates to Enhabit’s home health and hospice operations, capital structure, and governance.
Investors and researchers can use this filings archive to follow Enhabit’s reported net service revenue trends, segment performance, executive and director arrangements, and the regulatory context around its home-based care business, all sourced from the company’s official submissions to the SEC’s EDGAR system.
Enhabit, Inc. (EHAB) – Form 4 Insider Transaction
Director Charles M. Elson reported the acquisition of 2,579 common-stock deferred stock units on 10 Jul 2025 under the company’s Deferred Director Compensation Plan. The units were valued at $7.27 per share, representing roughly $18.8 thousand in equity received in lieu of a cash retainer. Following the award, Elson’s total direct beneficial ownership rises to 75,073 shares.
- Transaction code “A” denotes an award or grant, not an open-market purchase.
- The incremental increase is about 3.6 % versus Elson’s prior stake of roughly 72,494 shares.
- No derivative securities were involved in this filing.
The filing signals routine compensation rather than a discretionary purchase, so market impact is expected to be limited. However, growing insider ownership can be interpreted as modestly positive for alignment with shareholder interests.
FAQ
What is the current stock price of Enhabit (EHAB)?
What is the market cap of Enhabit (EHAB)?
